Summary of Pacira BioSciences FY Conference Call (January 14, 2026) Company Overview - **Company**: Pacira BioSciences (NasdaqGS:PCRX) - **Mission**: Deliver innovative, non-opioid pain management therapies to transform lives [2][3] - **Sales**: Reported unaudited sales of $726 million for the previous year [2] - **Employees**: Over 800 engaged employees [2] - **Patients Served**: More than 18 million patients helped to date [2] Product Portfolio - **Key Products**: - **Exparel**: Flagship product for nerve block - **Zilretta**: Long-acting corticosteroid for osteoarthritis pain - **Iovera**: Medical device using cryoneurolysis for pain management [3] Strategic Developments - **5x30 Strategy**: Aims to help over 3 million patients by 2030, achieve double-digit top-line growth, expand profitability by five points, add five new programs to the pipeline, and establish five partnerships [6][7] - **Partnerships**: - **Johnson & Johnson MedTech**: Triples reach for Zilretta [9] - **LG Chem**: Gains commercial rights for Exparel in Asia-Pacific, with potential for Zilretta sales [10] - **Intellectual Property**: Strong IP estate with 21 patents, providing robust defense against future Paragraph IV filers [5][12] Financial Performance - **Stock Performance**: 40% increase in stock price from January to December [5] - **Profitability**: Expected margins of 80%-82% for the current year [7] - **Share Buyback**: $150 million worth of stock repurchased, reducing outstanding shares to 41 million [11] Pipeline and Data Catalysts - **Upcoming Data Catalysts**: - **PCRX201**: Local gene therapy with promising phase one results [8][22] - **Iovera Spasticity**: Interim readout expected in the first half of the year [21] - **Zilretta for OA of the Shoulder**: Registrational study readout anticipated [21] Market Access and Growth Strategy - **NOPAIN Legislation**: Aimed at reducing opioid prescriptions; 102 million lives covered by the end of the year [19] - **Market Access**: Over 90% of business contracted, with ongoing efforts to educate stakeholders [20][44] - **Volume Growth**: Notable growth in the second half of the year, with 9% and 7% volume growth in Q3 and Q4 respectively [36] Challenges and Future Outlook - **Behavior Change**: Ongoing efforts to drive behavior change among healthcare professionals regarding non-opioid pain management [31] - **Market Education**: Continued focus on educating physicians and patients about the benefits of non-opioid options [41][43] - **Long-term Potential**: Exploration of additional indications for PCRX201, including potential for repeat dosing and expansion to other joints [33][35] Conclusion - **Overall Sentiment**: The company is optimistic about its growth trajectory, driven by a strong product pipeline, strategic partnerships, and a commitment to transforming pain management [28][30]

Summary of Pacira BioSciences Conference Call Company Overview - **Company**: Pacira BioSciences (NasdaqGS:PCRX) - **Focus**: Musculoskeletal pain management - **Products**: - Exparel: Flagship nerve block product - Zilretta: Long-acting steroid for osteoarthritis - Iovera: Medical device using cryoneurolysis for pain relief - **Future Goals**: 5x30 initiative aiming for significant growth and development by 2030 [1][2] Financial Performance - **Revenue Projection**: Expected to be around $750 million for the year, with Exparel contributing over $500 million [4] - **EBITDA**: Anticipated to be around $200 million [4] - **Growth Drivers**: Exparel is the main growth driver, with ongoing investments in commercial medical market access [3][5] Exparel Growth Dynamics - **Reimbursement Catalyst**: Introduction of "no pain" reimbursement for Medicare patients, allowing separate reimbursement for Exparel [6] - **Volume Growth**: Year-over-year volume increases of 3%, 6%, and 9% in the first three quarters, respectively [7] - **Adoption Challenges**: Larger institutions are slower to adopt due to organizational complexities [12][13] Market Access and Sales Strategy - **GPO Contracts**: Over 80% of business contracted under Group Purchasing Organizations (GPOs) [10] - **Sales Force Structure**: Dedicated sales forces for Exparel, Zilretta, and Iovera to enhance focus and efficiency [17][18] - **Education Efforts**: Increased focus on educating payers and healthcare professionals about the benefits of Exparel [16] Pipeline and Future Products - **PCRX-201**: A gene therapy targeting osteoarthritis of the knee, with a completed Phase I program and a recently enrolled Phase 2A program [29][30] - **Market Potential**: Positioned as a gene therapy for the masses, with a focus on local administration and improved safety profiles [29][31] - **Phase 2 Program**: Aiming for transformative pain relief extending beyond the current standard of care [32] Manufacturing and Margins - **Manufacturing Improvements**: Transition to a 200-liter process has improved production reliability and reduced waste, leading to enhanced gross margins [26][27] - **Margin Guidance**: Expected to achieve at least a five-point margin improvement over five years [27] International Expansion - **Global Market Opportunities**: Plans to explore markets outside the U.S. without the need for additional clinical studies [24] Conclusion - **Outlook**: Anticipated continued growth driven by Exparel, Zilretta, and Iovera, alongside new product developments and strategic partnerships [21][23]